CTN Bulletin logo
June 15, 2022 

CTN Gender Special Interest Group (SIG)

CTN SnowflakeChaired by Shelly F. Greenfield, MD, MPH and Aimee Campbell, PhD, the CTN Gender SIG (GSIG) is a resource to provide consultation to members of the CTN addressing gender-related questions in the development planning, executive, and analysis of current and new studies. Members of the GSIG help identify critical areas of investigation pertaining to substance use disorder (SUD) treatment for women (including adolescent girls and transgender women) and other gender diverse people (e.g., non-binary individuals) historically underrepresented in and excluded from research trials. The GSIG has developed concepts, conducted secondary data analyses, and critical reviews pertaining to sex and gender differences and gender-related issues in SUD treatment. In addition, the GSIG offers consultation to members of the CTN regarding gender-related questions in the design and analysis of new protocols.

Anyone with an interest in learning more and contributing to gender-related issues in substance use disorder treatment is welcome! Meetings are typically about 60 minutes long and are held every month on the 2nd Wednesday via Zoom (1pm EST).

Find out more here.

· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·

New Mailing Address for the CCTN

The CCTN Address has changed! Please contact us at:

Center for the Clinical Trials Network, NIDA, NIH
3 White Flint North, MSC 6022
16701 Industrial Drive
Gaithersburg, MD  20877

· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·

illustration of summer sunAre You Presenting at a Summer Conference?

Submit your CTN-related presentation slides to the CTN Dissemination Library at ctnlib@uw.edu!

If you send them in advance, we can prepare a URL you can use to share the slides with your audience.

Please make sure there isn't unpublished data in your slide set (or remove those slides before submitting), and be sure to include information about where you will be presenting!

CTN Trial Progress

GraphRandomizations for Active Studies as of the June 13 Trial Progress Report.

CTN-0060-A-1 - Enrolled 811 

CTN-0080 - Enrolled 90

CTN-0097 - Enrolled 393

CTN-0098 - Enrolled 47

CTN-0099 - Enrolled 966

CTN-0099-A-1 - Enrolled 86

CTN-0100
Discontinuation - Enrolled 51
Retention - Enrolled 360

CTN-0101 - Enrolled 153

CTN-0107 - Enrolled 50

CTN-0108 - Enrolled 25

This project is supported by a grant from the National Institute on Drug Abuse to the University of Washington Additions, Drug & Alcohol Institute, but the information on this site has not been reviewed by NIDA and does not necessarily reflect the views of the Institute.


· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·

New Tool from the CCC and DSC: Smartsheet Study Schedule

NIDA CCC and DSC are excited to announce the upcoming roll out of the cloud-based, Smartsheet Study Schedule (SSS). Designed to replace the current Excel-based Protocol Timeline Calculator, the Smartsheet Study Schedule is a template comprised of standard tasks required for the execution, maintenance, and closeout of a NDAT CTN study. This schedule uses predetermined anchors to project milestones and target dates for a study based on standard timeframes.

The purpose of this initiative is to continue to support Lead Investigators with ownership of their respective study schedules as outlined in CTN Policies and Procedures. Additionally, the tool allows for communication of real-time updates between the Lead Investigators and Emmes CCC and DSC staff to further drive efficiency and increase transparency within NDAT CTN studies.

Roll out of this initiative will begin with a demo of the tool being presented at the CTN Node Coordinators call on June 23rd at 3pm ET. This new process will then be incorporated into all studies (both Emmes and non-Emmes supported) currently in the protocol development stage and any new studies moving forward. Reference materials and live support will also be available to ensure a smooth transition in adopting this new process and tool.

· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·

News from the Nodes

Greater Southern California Node

J Addict Med coverThe Greater Southern California Node has a new paper out:

Social Determinants of Mortality of COVID-19 and Opioid Overdose in American Rural and Urban Counties. Zhu Y, et al. Journal of Addiction Medicine 2022;16(1):e52-e55.

In this node-supported study, researchers analyzed county-level data on COVID-19 mortality from January 1 to May 31, 2020, and on opioid overdose mortality during 2014-2018.

Analysis found that rural counties with high proportions of racial/ethnic minorities and urban counties with high unemployment rates are at high mortality risk for COVID-19 and opioid overdose.

Find out more about this new paper here.

 

 



Western States Node

WS NodeThe CTN Western States Node and the Northwest and Pacific Southwest ATTCs are partnering again this June to bring you their next joint webinar:

Emergency Department-Initiated Buprenorphine for Opioid Use Disorder
June 30, 2022 | 11am-12:30pm PT | Register here

This webinar, presented by Gail D'Onofrio, MD, will focus on the crucial role of the emergency department (ED) in recognizing and treating opioid use disorder (OUD) patients with evidence-based medications for addiction treatment. The opioid epidemic combined with the COVID-19 pandemic has greatly escalated the need to mitigate the morbidity and mortality associated with rising rates of fentanyl use. Dr. D'Onofrio will share data supporting the use of buprenorphine in the ED and discuss the consequences of not initiating treatment, barriers to implementation of ED buprenorphine, and components of successful integration of an ED program with community partnerships. She will also share current research by emergency physicians regarding innovative strategies like high-dose induction and use of an extended release 7-day formulation of buprenorphine.

1.5 CME or CE credits available.

 

· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·

New in the CTN Dissemination Library

Did you know that you can get free full-text for over 600 CTN-related journal articles in the CTN Dissemination Library? For all the others, if you can’t access it yourself, just click “Email CTN Library (free)” under “How to Get the Item” and the CTN Dissemination Librarian can send you a PDF!

Development and Implementation of a Prescription Opioid Registry Across Diverse Health Systems. Ray GT, et al. JAMIA Open 2022;5(2):ooac030. CTN-0084

Comparison of Medical Cannabis Use Reported on a Confidential Survey vs Documented in the Electronic Health Record Among Primary Care Patients. Lapham GT, et al. JAMA Network Open 2022;5(5):e2211677. CTN-0077-OT

Social Determinants of Mortality of COVID-19 and Opioid Overdose in American Rural and Urban Counties. Zhu Y, et al. Journal of Addiction Medicine 2022;16(1):e52-e55. Greater Southern California Node

Participants' Treatment Perspectives on a Clinical Trial on the Use of Extended-Release Naltrexone for Substance Use Disorders: Considerations for Future Clinical Research. Bardwell G, et al. Journal of Addiction Medicine 2021;15(5):390-395. CTN-0055

· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·

Upcoming Presentation Opportunities

Woman presenting at a conference in front of an audiencePolysubstance Use Symposium in NYC: Abstract Deadline is July 1
October 20-21, 2022 | New York City

The NYU Grossman School of Medicine’s Center for Opioid Epidemiology and Policy is hosting the first Polysubstance Use Symposium in New York City (in person at the NYU Kimmel Center), October 20-21, 2022. This event will accelerate knowledge of polysubstance use--the use of two or more substances--by bringing together an interdisciplinary group of stakeholders with an emphasis on opportunities for early-career and underrepresented researchers.

Cost to attend is $20. Registration is open!

The planning committee is now accepting abstract submissions. Abstracts should not exceed 350 words and should fit within one of the 3 topic domains--see submission form for more information.

15th Annual Conference on the Science of Dissemination and Implementation in Health: Abstract Deadline is July 19
December 11-14, 2022 | Washington DC

The 15th Annual Conference on the Science of Dissemination and Implementation in Health is now accepting abstract submissions (note: this event will be in-person this year in Washington DC).

Sponsored by Academy Health and the National Institutes of Health, this year’s theme, (Re)Building Better Systems: Being Proactive, Nimble, and Responsive, will build on lessons learned about rapidly changing community health and clinical settings to envisioning new models for conducting D&I science that respond to the shifting needs of diverse systems and populations, and use flexible and rigorous methodologies to anticipate challenges and ongoing change.

Deadline for abstract submissions: July 19, 2022 at 5pm ET.

Find out more and submit your abstract here!

· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·

New SAMHSA Resource

Preliminary Findings from Drug-Related Emergency Department Visits, 2021: Results from the Drug Abuse Warning Network. An analysis of 2021 preliminary data presents (1) nationally representative weighted estimates for the top five drugs in drug-related ED visits, (2) the assessment of monthly trends and drugs involved in polysubstance ED visits in a subset of sentinel hospitals, and (3) the identification of drugs new to DAWN’s Drug Reference Vocabulary.

New from the ATTC

Engaging Beyond the Current LGBTQIA “Lingo” - by Paul Warren, LMSW, Research Project Director at the New York State Psychiatric Institute. ATTC Messenger, June 2022.

SUD and Beyond: Schools Use NIATx To Improve Youth Suicide Prevention Efforts - by Kristina Spannbauer, Great Lakes ATTC, MHTTC, & PTTC Communications Specialist. ATTC/NIATx Service Improvement Blog.


     

Published by the CTN Dissemination Library of the Pacific Northwest Node
Addictions, Drug & Alcohol Institute, University of Washington

This project is supported by a grant from the National Institute on Drug Abuse to the University of Washington Addictions, Drug & Alcohol Institute, but the information on this site has not been reviewed by NIDA and does not necessarily reflect the views of the Institute.

Unsubscribe | Subscribe